Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer

Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer); By End-user (Hospital, Clinics, Others); By Regions, Segments & Forecast, 2024 - 2032

The global cancer immunotherapy market size is expected to reach USD 261.39 billion by 2032 according to a new study by Polaris Market Research. The report “Cancer Immunotherapy Market Share, Size, Trends, Industry Analysis Report By Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators); By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer); By End-user (Hospital, Clinics, Others); By Regions, Segments Forecast, 2020 - 2026”gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing pool of patients and greater mortality rates through cancer worldwide have encourage the need for cancer immunotherapy. Cancer is the second leading cause mortalities in 2019, with continuous rise in the number of cancer patient across the globe, as per the report published by WHO. Furthermore, it is estimated that 1 out of 6 deaths occurs due to cancer every year across the globe. As per WHO, nearly one-third of the mortalities from cancer are due to 5 leading behavioral and dietary risk, which includes low fruit and vegetable intake, high body mass index, lack of physical activity, alcohol consumption, and tobacco use. Tobacco is one of the leading factors for the rise in the prevalence of cancer and mortalities that accounted to nearly 22% of the global population. Rising number of cancer patients is the major factor for the growth of global diagnostic biomarker market.

According to WHO, in 2015, there were around 17.6 million cases related to cancer that increases to 18.1 million cases in 2018 and nearly 9.6 million mortalities. Cancer immunotherapy is widely used in treating prostate cancer, blood cancer, melanoma, lung, breast, colorectal and other chronic diseases. In the breast cancer segment, there is relatively higher demand for immunotherapy. The demand for immunotherapy in pulmonary cancer is also significantly increasing. Furthermore, the growing population of smokers and the alarming increase in urban air pollution are the main factors driving the market development. Therefore, increasing prevalence of cancer across the globe augmenting the global market for cancer immunotherapy.

Moreover, the global market for cancer immunotherapy is driven by a growing amount of approvals for new immunotherapy drugs. In the global cancer therapy industry, cancer immunotherapy has led to unprecedented changes. Over the past few years, cancer immunotherapy has generated fresh waves of optimism across the global oncology industry, which has unmasked enormous innovative potential. Studies now look for fresh goals and procedures to overcome the lapses in conventional treatment after years of jostling about the way the body can use its immune system. The paradigm shift in the management of cancer, relative to existing conventional therapies based on features like relatively long-lived effects, exceptional specificity and enhanced survival rates was brought about by the introduction of cancer immunotherapy. This has led to the accelerated growth of the global market.

Moreover, emerging market such as Asia-pacific has substantial opportunity in the market. The factors that will be favorable to the growth of the market in the emerging market includes increasing government expenditures on healthcare in Asian countries, and the presence of huge population suffering with colorectal cancer and other cancer types. The cancer cases in Asia are increasing at a rapid rate. According to the WHO, there were an estimated 4 million mortalities from cancer in Asia in 2016. Cancer is the leading cause of mortality in China as there are 4 million new cancer patients diagnosed every year.

The same condition is in South Korea, as there are more than 200,000 new cancer cases a year. The increase in cancer cases in Asia can be accounted to the lifestyle and demographic changes. According WHO The incidences of colorectal cancer India were estimated about 1,85,000 in 2017. Japan accounted 1,49,000 cases in the 2017 according to national cancer institute. The average annual increase in government healthcare spending in the US is 4.5% and less than 1.5% in the European Union. However, Asian countries increase in healthcare expenditure is more than 6%, which is higher than the developed nations. Japan has the highest growth in the healthcare. Thus, creating significant opportunity in the market.

Polaris Market research has segmented the cancer immunotherapy market report on the basis of:

Cancer Immunotherapy Type Outlook (Revenue, USD Billion, 2015 – 2026)

- Monoclonal Antibodies,

- Cancer Vaccines,

- Check Point Inhibitors & Immunomodulators

Cancer Immunotherapy Application Outlook (Revenue, USD Billion, 2015 – 2026)

- Lung Cancer

- Breast Cancer

- Colorectal Cancer

- Melanoma

- Prostate Cancer

- Head & Neck Cancer

Cancer Immunotherapy End User Outlook (Revenue, USD Billion, 2015 – 2026)

- Hospitals

- Clinics

- Others

Cancer Immunotherapy Regional Outlook (Revenue, USD Million, 2015 – 2026)

- North America

U.S.

Canada

- Europe

UK

Germany

France

Italy

Spain

- Asia Pacific

India

Japan

China

South Korea

- Latin America

Brazil

Mexico

Colombia

- Middle East & Africa

Saudi Arabia

South Africa

Israel

UAE